AK117/Placebo with Azacitidine
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
What's the purpose of the trial?
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C28.94888%2C-81.29867%7C39.023998%2C-77.133698%7C40.852001%2C-81.428497%7C38.638401%2C-90.263397%7C32.783401%2C-79.9478%7C34.05223%2C-118.24368%7C39.685799%2C-104.830002%7C41.304827%2C-72.935904%7C39.2137%2C-76.882365%7C35.903011%2C-79.053528)
Participating Centers
There are 10 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- AK117 is a kind of drug called a monoclonal antibody that targets the CD47 protein which is highly expressed by some cancers.
- Azacitidine is a type of chemotherapy called a hypomethylating agent that interferes with the growth and spread of cancer cells in the body.
- Placebo is a substance that has no therapeutic effect and can be used as a control in testing new drugs in clinical trials.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.